BR112012017837A2 - método para determinar se o vírus da peritonite infecciosa felina (fipv) está presente em uma amostra, par de primer compreendendo uma sequência de ácido nucléico isolado ou recombinante, sonda, anticorpo ou equivalente funcional dirigido especificamente contra um epítopo de uma proteína de perfuração fipv, composição imunogênica e uso - Google Patents

método para determinar se o vírus da peritonite infecciosa felina (fipv) está presente em uma amostra, par de primer compreendendo uma sequência de ácido nucléico isolado ou recombinante, sonda, anticorpo ou equivalente funcional dirigido especificamente contra um epítopo de uma proteína de perfuração fipv, composição imunogênica e uso

Info

Publication number
BR112012017837A2
BR112012017837A2 BR112012017837A BR112012017837A BR112012017837A2 BR 112012017837 A2 BR112012017837 A2 BR 112012017837A2 BR 112012017837 A BR112012017837 A BR 112012017837A BR 112012017837 A BR112012017837 A BR 112012017837A BR 112012017837 A2 BR112012017837 A2 BR 112012017837A2
Authority
BR
Brazil
Prior art keywords
fipv
perforating
epitope
antibody
probe
Prior art date
Application number
BR112012017837A
Other languages
English (en)
Other versions
BR112012017837B1 (pt
Inventor
Herman F Egberrink
Hui Wen Chang
Petrus Josephus Marie Rottier
Original Assignee
Univ Utrecht Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utrecht Holding Bv filed Critical Univ Utrecht Holding Bv
Publication of BR112012017837A2 publication Critical patent/BR112012017837A2/pt
Publication of BR112012017837B1 publication Critical patent/BR112012017837B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012017837-7A 2010-01-18 2011-01-18 método para determinar se o vírus da peritonite infecciosa felina (fipv) está presente em uma amostra e uso BR112012017837B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10151001.4 2010-01-18
EP10151001 2010-01-18
EP10151340 2010-01-21
EP10151340.6 2010-01-21
PCT/NL2011/050027 WO2011087366A1 (en) 2010-01-18 2011-01-18 Means and methods for distinguishing fecv and fipv

Publications (2)

Publication Number Publication Date
BR112012017837A2 true BR112012017837A2 (pt) 2016-03-29
BR112012017837B1 BR112012017837B1 (pt) 2021-02-17

Family

ID=43795094

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017837-7A BR112012017837B1 (pt) 2010-01-18 2011-01-18 método para determinar se o vírus da peritonite infecciosa felina (fipv) está presente em uma amostra e uso

Country Status (13)

Country Link
US (1) US9796996B2 (pt)
EP (1) EP2526209B1 (pt)
JP (1) JP5926194B2 (pt)
KR (1) KR20120130759A (pt)
CN (1) CN102791886B (pt)
AU (1) AU2011205863B2 (pt)
BR (1) BR112012017837B1 (pt)
CA (1) CA2787385C (pt)
DK (1) DK2526209T3 (pt)
ES (1) ES2534362T3 (pt)
MX (1) MX2012008387A (pt)
PL (1) PL2526209T3 (pt)
WO (1) WO2011087366A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107586884B (zh) * 2017-10-25 2020-08-18 东北农业大学 一种用于猫传染性腹膜炎病毒检测的rt-pcr引物组,含有该引物组的试剂盒及其应用
CN108559789A (zh) * 2017-12-29 2018-09-21 苏州点晶生物科技有限公司 猫冠状病毒荧光ema检测引物组、试剂盒和检测方法
CN110904271A (zh) * 2019-11-27 2020-03-24 武汉康湃特生物科技有限公司 一种诊断猫传染性腹膜炎的新方法
CN111518955A (zh) * 2020-05-15 2020-08-11 广东省实验动物监测所 快速鉴别猫肠道冠状病毒和猫传染性腹膜炎病毒的hrm引物对、试剂盒及方法
KR102392774B1 (ko) * 2020-05-18 2022-04-29 포스트바이오(주) 고양이 코로나바이러스 검출을 위한 rt-pcr용 조성물
CN112415202A (zh) * 2020-11-06 2021-02-26 爱若维生物科技(苏州)有限公司 一种检测猫冠状病毒的试纸条及其制备方法、试剂盒、检测方法
CN112779353A (zh) * 2020-12-31 2021-05-11 上海基灵生物科技有限公司 一种用于检测猫冠状病毒或其相关疾病的核酸组合物及其试剂盒和应用
CN117417902B (zh) * 2023-10-27 2024-05-03 华中农业大学 一种重组致弱的猫传染性腹膜炎病毒及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246831A (en) * 1990-09-21 1993-09-21 Synbiotics Corporation Feline infectious peritonitis virus test utilizing monoclonal idiotypic and anti-idiotypic antibodies
NZ240558A (en) * 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease
US20040063093A1 (en) * 1992-04-08 2004-04-01 Pfizer, Inc. Recombinant feline coronavirus S proteins
US5719028A (en) 1992-12-07 1998-02-17 Third Wave Technologies Inc. Cleavase fragment length polymorphism
US5670156A (en) * 1993-02-18 1997-09-23 Parhelion Corporation Feline infectious peritonitis vaccine and method of preparation
WO1995008575A1 (en) * 1993-09-21 1995-03-30 Cornell Research Foundation, Inc. Monoclonal antibodies specific for feline infectious peritonitis virus
SE9400522D0 (sv) 1994-02-16 1994-02-16 Ulf Landegren Method and reagent for detecting specific nucleotide sequences
JP3565579B2 (ja) * 1994-06-10 2004-09-15 社団法人北里研究所 ネコ伝染性腹膜炎i型ウイルスのスパイク蛋白質遺伝子rnaに対応するdna
US5942391A (en) 1994-06-22 1999-08-24 Mount Sinai School Of Medicine Nucleic acid amplification method: ramification-extension amplification method (RAM)
US5858373A (en) * 1995-12-01 1999-01-12 Virogenetics Corporation Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
WO2002066686A1 (en) 2001-02-19 2002-08-29 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Feline infectious peritonitis viruses (fipv) diagnosis
JP2004033080A (ja) * 2002-07-02 2004-02-05 Japan Science & Technology Corp ヒト遺伝子の一塩基多型(6)
JP4242607B2 (ja) * 2002-07-04 2009-03-25 学校法人北里研究所 ネコ伝染性腹膜炎ワクチン
ATE376008T1 (de) * 2002-07-23 2007-11-15 Nuplex Resins Bv Verfahren zur polymerisation ethylenisch ungesättigter monomere
US7897744B2 (en) * 2003-04-28 2011-03-01 The Public Health Agency Of Canada SARS virus nucleotide and amino acid sequences and uses thereof
EP1751311A2 (en) * 2004-05-26 2007-02-14 Rosetta Genomics ltd Viral and viral associated mirnas and uses thereof
WO2006046979A2 (en) * 2004-06-30 2006-05-04 Kansas State University Research Foundation Feline infectious peritonitis (fip) and systemic multi-organ coronavirus biomarkers and screening methods
WO2009039244A2 (en) * 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
US9044486B2 (en) * 2008-04-02 2015-06-02 Cornell University Method for prophylaxis or treatment of feline infectious peritonitis
GB0809898D0 (en) * 2008-06-02 2008-07-09 Univ Ghent Methods and compositions in the treatment of coronaviruses

Also Published As

Publication number Publication date
PL2526209T3 (pl) 2015-08-31
JP5926194B2 (ja) 2016-05-25
BR112012017837B1 (pt) 2021-02-17
US20130071833A1 (en) 2013-03-21
ES2534362T3 (es) 2015-04-21
DK2526209T3 (en) 2015-04-07
CN102791886B (zh) 2015-04-08
JP2013516983A (ja) 2013-05-16
MX2012008387A (es) 2012-11-23
KR20120130759A (ko) 2012-12-03
CA2787385C (en) 2018-12-11
EP2526209A1 (en) 2012-11-28
CA2787385A1 (en) 2011-07-21
AU2011205863A1 (en) 2012-08-09
CN102791886A (zh) 2012-11-21
EP2526209B1 (en) 2015-03-18
WO2011087366A1 (en) 2011-07-21
AU2011205863B2 (en) 2014-08-28
US9796996B2 (en) 2017-10-24

Similar Documents

Publication Publication Date Title
BR112012017837A2 (pt) método para determinar se o vírus da peritonite infecciosa felina (fipv) está presente em uma amostra, par de primer compreendendo uma sequência de ácido nucléico isolado ou recombinante, sonda, anticorpo ou equivalente funcional dirigido especificamente contra um epítopo de uma proteína de perfuração fipv, composição imunogênica e uso
BR112014000341A2 (pt) proteína de ligação ao antígeno, método para tratamento de um paciente com uma doença, uso de uma proteína de ligação ao antígeno, ácido nucleico, e, célula hospedeira
WO2008145401A3 (en) Mutated parvovirus structural proteins as vaccines
BR112014029274A2 (pt) anticorpo isolado, composição farmacêutica, uso do anticorpo, método para tratar infecção rábica, kit para tratar infecção rábica, kit para detectar vírus rábico, ácido nucleico isolado, e, célula hospedeira.
AR089752A1 (es) Anticuerpos anti-lrp5 y metodos de uso
BR112012004823A2 (pt) composto de ligação, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos pra produzir um polipeptídeo e para intensificar uma resposta imune em um sujeiro humano, composição farmacêutica, e, anticorpo ou fragmento de ligação de antígeno
CL2014003051A1 (es) Anticuerpo de unión a hemaglutinina (ha) de diversos virus de la influenza; ácido nucleico que lo codifica; vector; célula huésped; método de elaboración; método de detección de virus de la influenza; composición farmacéutica; vacuna; y kit.
BR112013014527A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
Pennisi et al. Serological and molecular prevalence of Leishmania infantum infection in cats from Southern Italy
CL2013000019A1 (es) Proteina fijadora de antigeno aislada que fija el factor de crecimiento epidermico fijador de heparina (hg-egf); molecula de acido nucleico que la codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad hiperproliferativa.
BRPI0922106A2 (pt) anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
EP3587439A3 (en) Improved quantification of vaccine compositions
BR112014026990A2 (pt) anticorpo , ácido nucleico , vetores , célula hospedeira , composição farmacêutica , uso de um anticorpo e método para o tratamento de um paciente com necessidade de terapia.
BRPI0810211A2 (pt) Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira.
EP2641914A4 (en) MONOCLONAL ANTIBODY FOR THE RECOGNITION OF HUMAN PAPILLOMA (HPV) PROTEIN L2 AND METHOD FOR MEASURING HPV NEUTRALIZING ANTIBODIES THEREWITH
BR112012002137A2 (pt) método para um polipeptídeo e/ou vírus de interesse em uma cultura de célula contínua,e, composição
BRPI0916964A2 (pt) polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
WO2011031497A3 (en) Quantitative fluorescent protein standards
BR112016009460A8 (pt) método para detectar a presença de anticorpos neutralizantes, e, kit
BR112016009827A2 (pt) Método in vitro para concentrar patógenos infecciosos presentes em uma amostra biológica obtida a partir de um indivíduo sob suspeita de estar infectado com os ditos patógenos, concentrador e kit
BRPI0820177A2 (pt) Métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas e para detectar uma proteína alvo, sistema para produzir um extrato de proteína, kit para produzir um extrato de proteína de células fixadas ou não-fixadas, e, método para extrair uma proteína viral alvo de uma amostra celular
WO2014052433A3 (en) Method and system for analysis of protein and other modifications on dna and rna
BR112016004324A2 (pt) anticorpos
BR112016014010A2 (pt) métodos para detectar anticorpos contra vírus da febre suína clássica tipo selvagem (csfv), para diferenciação entre animais infectados com csfv tipo selvagem e animais que foram vacinados contra csfv e para controlar uma infecção com csfv tipo selvagem, kit de teste de diagnóstico, e, uso de um carreador
BR112013000340A2 (pt) anticorpo isolado que se liga a neuropilina-1 (nrp1), ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado e método de detecção da presença de nrp1 em uma amostra biológica

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.20 NA RPI NO 2523 DE 14/05/2019 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/02/2021, OBSERVADAS AS CONDICOES LEGAIS.